High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: A multi-institutional study of Japanese society of therapeutic radiology and oncology 2006-2007 (study of JASTRO 2006-2007)

Japanese Journal of Clinical Oncology

Volumn 40, Issue 8, 2010, Pages 795-799

  Niibe, Yuzuru ^a   Kenjo, Masahiro ^b   Onishi, Hiroshi ^c   Ogawa, Yoshihiro ^d   Kazumoto, Tomoko ^e   Ogino, Ichiro ^f   Tsujino, Kayoko ^g   Harima, Yoko ^h   Takahashi, Takeo ⁱ   Anbai, Akira ^j   Tsuchida, Emiko ^k   Toita, Takafumi ^l   Takemoto, Mitsuhiro ^m   Yamashita, Hideomi ⁿ   Hayakawa, Kazushige ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g HYOGO CANCER CENTER   (Japan)

^h KANSAI MEDICAL UNIVERSITY   (Japan)

ⁱ SAITAMA MEDICAL UNIVERSITY   (Japan)

^j AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^l UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^m OKAYAMA UNIVERSITY HOSPITAL   (Japan)

ⁿ UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Adenocarcinoma of the uterine cervix multi; High dose rate intracavitary brachytherapy; Institutional study

Indexed keywords

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; OVERALL SURVIVAL; RADIATION DOSE; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOMA, ADENOSQUAMOUS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS;

EID: 77955238693     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq053     Document Type: Article

References (13)

1. Toita T, Takizawa Y, Sueyama H, Sueyama H, Kushi A, Kakihana Y, et al. Radical radiotherapy for adenocarcinoma of the uterine cervix. Strahlenther Onkol 1994;170:277-80.
2. Suzuki Y, Nakano T, Arai T, Morita S, Tsujii H, Oka K. Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2000;47:1229-34.
3. Niibe Y, Hayakawa K, Kanai T, Tsunoda S, Arai M, Jobo T, et al. Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol 2006;27:47-9.
4. Toita T, Sakumoto K, Higashi M, Ogawa K, Kakinohana Y, Shinzato S, et al. Therapeutic value of neoadjuvant intra-arterial chemotherapy (cisplatin) and irradiation for locally advanced uterine cervical cancer. Gynecol Oncol 1997;65:421-4.
5. Hareyama M, Sakata K, Ouchi A, Shirato H, Nishioka T, Nishio M, et al. High-dose rate versus low-dose rate intracavitary therapy for carcinoma of the uterine cervix: a randomized study. Cancer 2002;94:117-24.
6. Nakano T, Kato S, Ohono T, Tsujii H, Sato S, Fukihisa K, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 2005;103:92-101.
7. Eifel PJ, Bruke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995;59:38-44.
8. Grigsby PW, Perez CA, Kuske RR, Camel HM, Kao MS, Galakatos AE, et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol 1998;12:289-96.
9. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;48:201-11.
10. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med 1999;340:1137-43.
11. Vrdoljak E, Omrcen T, Novakovic ZS, Jelavic TB, Prskalo T, Hrepic D, et al. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women locally advanced carcinoma of the uterine cervix-final results of a prospective phase II-study. Gynecol Oncol 2006;103:494-9.
12. Zarba JJ, Jaremtchuk AV, Gonzalez Jazey P, Keropian M, Castagnino R, Mina C, et al. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol 2003;14:1285-90.
13. Niibe Y, Watanabe J, Tsunoda S, Arai M, Arai T, Kawaguchi M, et al. Concomitant expression of HER2 nad HIF-1α is a poor prognostic factor in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501). Eur J Gynaecol Oncol, in press.